Axsome Therapeutics is trading 4.4% lower at $185.34, with no confirmed direct catalyst identified for the decline. - A September 29 Deutsche Bank update maintained its Buy rating but lowered its price target from $280 to $267; available reporting does not establish that the revision caused the drop. - No clear company announcement was found. Broader markets were under pressure amid sharply weaker consumer confidence and softer job openings, though supplied index moves were modest.